The synthesis of a pyrimidine analog, 3′‐deoxy‐3′‐[ 18 F]‐fluoro‐1‐ β ‐ D ‐xylofuranosyluracil ([ 18 F]‐FMXU) is reported. 5‐Methyluridine 1 was converted to its di‐methoxytrityl derivatives 2 and 3 as a mixture. After separation the 2′,5′‐di‐methoxytrityluridine 2 was converted to its 3′‐triflate 4 followed by derivatization to the respective N 3 ‐ t ‐Boc product 5 . The triflate 5 was reacted with tetrabutylammonium[ 18 F]fluoride to produce 6 , which by acid hydrolysis yielded compound 7 . The crude preparation was purified by HPLC to obtain the desired product [ 18 F]‐FMXU. The radiochemical yields were 25–40% decay corrected (d. c.) with an average of 33% in four runs. Radiochemical purity was >99% and specific activity was >74 GBq/µmol at the end of synthesis (EOS). The synthesis time was 67–75 min from the end of bombardment (EOB).
No takes yet. Share an insight, caveat, or question.
Alauddin et al. (2005) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: